At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 218 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of Varenicline: Testing Individual Differences
In Brief
A Phase 4 clinical trial evaluating Placebo and Varenicline for Smoking Addiction. Completed, enrolled 218 participants across 1 site.
Detailed Summary
The study will evaluate the effectiveness of smoking cessation using Varenicline versus placebo. Effectiveness will be measured by the average number of cigarettes smoked per smoking day for up to 36 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Addiction
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedOct 2010
Primary CompletionFeb 2015
Study CompletionMar 2016
TodayJul 2026
First PostedOct 26, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.7 years ago
Interventions
Placebodrug
25mg look alike riboflavin tablets to match active study medication.
Vareniclinedrug
Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily